Sharif G M, Schmidt M O, Yi C, Hu Z, Haddad B R, Glasgow E, Riegel A T, Wellstein A
Lombardi Cancer Center, Georgetown University, Washington, DC, USA.
Oncogene. 2015 Nov 26;34(48):5879-89. doi: 10.1038/onc.2015.44. Epub 2015 Mar 16.
Metastasis of cancer cells involves multiple steps, including their dissociation from the primary tumor and invasion through the endothelial cell barrier to enter the circulation and finding their way to distant organ sites where they extravasate and establish metastatic lesions. Deficient contact inhibition is a hallmark of invasive cancer cells, yet surprisingly the vascular invasiveness of commonly studied cancer cell lines is regulated by the density at which cells are propagated in culture. Cells grown at high density were less effective at invading an endothelial monolayer than cells grown at low density. This phenotypic difference was also observed in a zebrafish model of vascular invasion of cancer cells after injection into the yolk sac and extravasation of cancer cells into tissues from the vasculature. The vascular invasive phenotypes were reversible. A kinome-wide RNA interference screen was used to identify drivers of vascular invasion by panning small hairpin RNA (shRNA) library-transduced noninvasive cancer cell populations on endothelial monolayers. The selection of invasive subpopulations showed enrichment of shRNAs targeting the large tumor suppressor 1 (LATS1) kinase that inhibits the activity of the transcriptional coactivator yes-associated protein (YAP) in the Hippo pathway. Depletion of LATS1 from noninvasive cancer cells restored the invasive phenotype. Complementary to this, inhibition or depletion of YAP inhibited invasion in vitro and in vivo. The vascular invasive phenotype was associated with a YAP-dependent upregulation of the cytokines IL6, IL8 and C-X-C motif ligand 1, 2 and 3. Antibody blockade of cytokine receptors inhibited invasion and confirmed that they are rate-limiting drivers that promote cancer cell vascular invasiveness and could provide therapeutic targets.
癌细胞转移涉及多个步骤,包括从原发肿瘤解离、穿过内皮细胞屏障进入循环系统,并找到通往远处器官部位的途径,在那里它们渗出并形成转移病灶。接触抑制缺陷是侵袭性癌细胞的一个标志,但令人惊讶的是,常用癌细胞系的血管侵袭性受培养中细胞传代密度的调节。高密度培养的细胞比低密度培养的细胞侵袭内皮单层的能力更弱。在将癌细胞注射到卵黄囊后进行血管侵袭以及癌细胞从脉管系统渗入组织的斑马鱼模型中也观察到了这种表型差异。血管侵袭表型是可逆的。通过在单层内皮细胞上淘选小发夹RNA(shRNA)文库转导的非侵袭性癌细胞群体,进行了全激酶组RNA干扰筛选,以鉴定血管侵袭的驱动因素。侵袭亚群的选择显示,靶向大肿瘤抑制因子1(LATS1)激酶的shRNA富集,该激酶在Hippo信号通路中抑制转录共激活因子Yes相关蛋白(YAP)的活性。从非侵袭性癌细胞中去除LATS1可恢复侵袭表型。与此互补的是,抑制或去除YAP可在体外和体内抑制侵袭。血管侵袭表型与细胞因子IL6、IL8以及C-X-C基序配体1、2和3的YAP依赖性上调有关。细胞因子受体的抗体阻断抑制了侵袭,并证实它们是促进癌细胞血管侵袭的限速驱动因素,可作为治疗靶点。